​

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RYTM Stock Forecast

Rhythm Pharmaceuticals (RYTM) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $126.00, with a high of $142.00 and a low of $110.00. This represents a 12.95% increase from the last price of $111.55.

- $30 $60 $90 $120 $150 High: $142 Avg: $126 Low: $110 Last Closed Price: $111.55

RYTM Stock Rating

Rhythm Pharmaceuticals stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 17 Strong Sell Sell Hold Buy Strong Buy

RYTM Price Target Upside V Benchmarks

TypeNameUpside
StockRhythm Pharmaceuticals12.95%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3514
Avg Price Target$126.00$125.80$96.29
Last Closing Price$111.55$111.55$111.55
Upside/Downside12.95%12.77%-13.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25410---14
Sep, 25410---14
Aug, 25410---14
Jul, 2548---12
Jun, 2548---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 17, 2025Corinne JohnsonGoldman Sachs$139.00$111.1825.02%24.61%
Oct 16, 2025Morgan Stanley$129.00$109.3517.97%15.64%
Sep 29, 2025Raghuram SelvarajuH.C. Wainwright$110.00$99.1610.93%-1.39%
Sep 25, 2025Jonathan WollebenJMP Securities$142.00$98.7643.78%27.30%
Aug 05, 2025Morgan Stanley$109.00$88.5723.07%-2.29%
Jul 10, 2025Leland GershellOppenheimer$110.00$89.0423.54%-1.39%
Jul 10, 2025Corinne JohnsonGoldman Sachs$97.00$89.048.94%-13.04%
Jul 09, 2025Michael UlzMorgan Stanley$95.00$89.006.74%-14.84%
Mar 05, 2025Stifel Nicolaus$78.00$52.9747.25%-30.08%
Mar 03, 2025H.C. Wainwright$70.00$52.4033.59%-37.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 17, 2025Goldman SachsBuyBuyhold
Oct 16, 2025Morgan StanleyOverweightOverweighthold
Sep 29, 2025H.C. WainwrightBuyBuyhold
Sep 25, 2025CitigroupOutperformOutperformhold
Sep 24, 2025Morgan StanleyOverweightOverweighthold
Aug 05, 2025Morgan StanleyOverweightOverweighthold
Jul 10, 2025GuggenheimBuyBuyhold
Mar 18, 2025NeedhamBuyBuyhold
Dec 31, 2024JefferiesBuyinitialise
Dec 05, 2024Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.96$-1.37$-3.51$-3.20$-4.34----
Avg Forecast$-3.02$-1.45$-3.53$-3.20$-4.12$-2.46$-0.75$2.25$6.28
High Forecast$-2.67$-1.28$-3.23$-3.16$-3.82$-1.98$0.06$2.74$7.69
Low Forecast$-3.55$-1.70$-4.09$-3.27$-4.39$-2.79$-2.04$1.22$5.49
Surprise %-1.99%-5.52%-0.57%-5.34%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$3.15M$23.64M$77.43M$130.13M----
Avg Forecast$52.97K$3.03M$21.41M$78.80M$126.00M$181.85M$333.83M$602.63M$970.38M
High Forecast$60.18K$3.44M$23.99M$80.69M$127.08M$208.91M$333.83M$602.63M$1.14B
Low Forecast$48.25K$2.76M$20.00M$77.29M$125.06M$164.87M$333.83M$602.63M$876.95M
Surprise %-4.19%10.43%-1.75%3.27%----

Net Income Forecast

$-300M $-150M $0 $150M $300M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-130.73M$-68.01M$-183.08M$-184.68M$-264.57M----
Avg Forecast$-174.03M$-83.43M$-203.78M$-184.68M$-236.88M$-137.49M$-42.97M$114.18M$362.02M
High Forecast$-153.88M$-73.77M$-186.37M$-182.31M$-220.43M$-113.92M$3.61M$158.06M$443.67M
Low Forecast$-204.80M$-98.19M$-235.71M$-188.66M$-253.33M$-161.06M$-117.89M$70.31M$316.71M
Surprise %-24.88%-18.49%-10.16%-11.69%----

RYTM Forecast FAQ

Is Rhythm Pharmaceuticals stock a buy?

Rhythm Pharmaceuticals stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rhythm Pharmaceuticals is a favorable investment for most analysts.

What is Rhythm Pharmaceuticals's price target?

Rhythm Pharmaceuticals's price target, set by 17 Wall Street analysts, averages $126 over the next 12 months. The price target range spans from $110 at the low end to $142 at the high end, suggesting a potential 12.95% change from the previous closing price of $111.55.

How does Rhythm Pharmaceuticals stock forecast compare to its benchmarks?

Rhythm Pharmaceuticals's stock forecast shows a 12.95% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rhythm Pharmaceuticals over the past three months?

  • October 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Rhythm Pharmaceuticals’s EPS forecast?

Rhythm Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.46, marking a -43.32% decrease from the reported $-4.34 in 2024. Estimates for the following years are $-0.75 in 2026, $2.25 in 2027, and $6.28 in 2028.

What is Rhythm Pharmaceuticals’s revenue forecast?

Rhythm Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $181.85M, reflecting a 39.75% increase from the reported $130.13M in 2024. The forecast for 2026 is $333.83M, followed by $602.63M for 2027, and $970.38M for 2028.

What is Rhythm Pharmaceuticals’s net income forecast?

Rhythm Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-137M, representing a -48.03% decrease from the reported $-265M in 2024. Projections indicate $-42.973M in 2026, $114.18M in 2027, and $362.02M in 2028.